Pilot Study on the Effects of Positive Electrostatic Charge as a Cancer Treatment for Late-Stage Metastatic Solid Tumors in Humans (Frontiers in Medicine)

Key Findings:

1. Patient Demographics and Study Design:
   • This human pilot study involved 41 patients with late-stage metastatic cancer, all with solid tumors that were unresponsive to conventional therapies such as chemotherapy and radiotherapy. These patients were considered for Positive Electrostatic Charge Therapy (PECT) as a last resort.
2. Tumor Response:
   • Significant Tumor Reduction: Over 80% of the patients exhibited a measurable reduction in tumor size, with some tumors shrinking by more than 50%. This significant reduction occurred without disease progression during the treatment period.
   • Stabilization of Disease: For patients who did not experience significant shrinkage, the disease was stabilized, with no further tumor growth observed.
3. Symptom Relief and Quality of Life:
   • Improvement in Symptoms: Patients reported relief from various cancer-related symptoms, such as pain and fatigue, leading to an overall improvement in quality of life. Some patients also experienced improved mobility and daily functioning.
4. Mechanism of Action:
   • The therapy is believed to work by disrupting cancer cell metabolism and inducing apoptosis through the modulation of the KRAS signaling pathway and increasing the Bax/Bcl2 ratio, favoring cell death.
   • No Damage to Normal Tissues: The treatment did not result in adverse effects on surrounding normal tissues, avoiding common side effects like skin burns or inflammation.
5. Safety Profile:
   • No Major Adverse Events: The treatment was well-tolerated by all patients, with no reports of severe side effects commonly associated with traditional cancer therapies. The absence of side effects like nausea, vomiting, or hair loss highlights the therapy’s safety.

Clinical Impact:

1. Potential as a Last-Resort Therapy:
   • For patients with late-stage metastatic cancer who have no other treatment options, PECT offers a potentially effective and safe alternative, extending life and improving quality of life.
2. Non-Invasive and Safe Alternative:
   • The non-invasive nature of PECT, coupled with its minimal side effects, positions it as a safer alternative to more toxic treatments like chemotherapy and radiotherapy.
   • This could be especially beneficial for patients who are not candidates for aggressive treatments.
3. Foundation for Larger Clinical Trials:
   • This pilot study provides a strong basis for larger, more comprehensive clinical trials. If similar results are replicated in larger populations, PECT could gain regulatory approval and become a standard treatment option for advanced cancers.
4. Broad Application Potential:
   • While this study focused on late-stage metastatic cancers, the underlying mechanisms suggest that PECT could be applicable to a variety of cancer types, potentially expanding its use across different patient groups.